Series A · Biotech · Oxford, United Kingdom · Founded 2019 · 11–50 employees
Ochre Bio is a biotechnology company developing RNA-based therapies for chronic liver diseases, including liver fibrosis, cirrhosis, and MASH. The company combines computational biology, machine learning, and deep multi-omic genomic phenotyping to discover targets. It validates RNA drug candidates directly in live non-transplantable human donor livers kept alive on perfusion machines in specialized Liver ICUs. In May 2024, Ochre Bio signed a major commercial R&D collaboration deal with Boehringer Ingelheim valued at over $1 billion in potential milestones.
No open roles listed right now.